IP Verse

Liquid Pharmaceutical Composition - EP3148510

EP3148510

ARES TRADING
Application Number
EP15724974A
Filing Date
May 15, 2015
Status
Revoked
Aug 5, 2022
Grant Date
Jun 27, 2018
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3148510B1 was granted to Ares Trading on Jun 27, 2018 following the initial filing on May 15, 2015 under the application number EP15724974A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BIOGENMar 26, 2019ADMISSIBLE
SAMSUNG BIOEPISMar 26, 2019ADMISSIBLE

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
DESCRIPTIONWO9729131
EXAMINATIONWO2017136433
INTERNATIONAL-SEARCH-REPORTWO2011104381
INTERNATIONAL-SEARCH-REPORTWO2013186230
INTERNATIONAL-SEARCH-REPORTWO2014039903
OPPOSITIONDK201800070Y
OPPOSITIONUS2014086931
OPPOSITIONWO2004091658
OPPOSITIONWO2006044908
OPPOSITIONWO2010129469
OPPOSITIONWO2011104381
OPPOSITIONWO2011161226
OPPOSITIONWO2012121754
OPPOSITIONWO2013164837
OPPOSITIONWO2014039903
OPPOSITIONWO2014066468
OPPOSITIONWO2014068021
OPPOSITIONWO2014068029
OPPOSITIONWO9729131

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- DAVIS, J. M. ET AL., BIOCHEMISTRY, (1987), vol. 26, pages 1322 - 1326-
DESCRIPTION- JONES, E. Y. ET AL., NATURE, (1989), vol. 338, pages 225 - 228-
DESCRIPTION- PENNICA, D. ET AL., NATURE, (1984), vol. 312, pages 724 - 729-
OPPOSITION- "8.2.1. Buffers", Lars Hovgaard et al, Pharmaceutical Formulation Development of Peptides and Proteins, (20130000), page 155, XP055579993-
OPPOSITION- "8.2.1. Buffers", Lars Hovgaard, Et Al, Pharmaceutical Formulation Development of Peptides and Proteins, (20130000), page 155, XP055579993-
OPPOSITION- "Alternative buffers for pharmaceutical anti-TNFalpha monoclonal antibody formulations", Prior Art Publishing , Publication No. PAPDEOTT002384, (20130206), pages 1 - 10, XP009188701-
OPPOSITION- anonymous, "Humira? Product Label", pages 1 - 80-
OPPOSITION- "Assessment Report for Simponi", EMA, (20080303), pages 1 - 70, XP055109044-
OPPOSITION- "Assessment Report for Simponi", EMA, (20090000), pages 1 - 70, XP055109044-
OPPOSITION- Humira? Product Label-
OPPOSITION- "Information for Simponi", FDA, (20090400), pages 1 - 47, XP055579990-
OPPOSITION- Prior Art Publishing , Publication No. PAPDEOTT002384, (20130206), XP009188701-
OPPOSITION- V.K. SHARMA et al., "Chapter 30: The Formulation and Delivery of Monoclonal Antibodies", Therapeutic Monoclonal Antibodies: From Bench to Clinic, (20090000), pages 675 - 709, XP055593299-
OPPOSITION- V.K. SHARMA et al., "The Formulation and Delivery of Monoclonal Antibodies", Therapeutic Monoclonal Antibodies: From Bench to Clinic, (20090000), pages 675 - 709, XP055593299-
OPPOSITION- Nicholas W Warne, "FORMULATION DEVELOPMENT OF PHASE 1-2 BIOPHARMACEUTICALS: AN EFFICIENT AND TIMELY APPROACH", Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, (20100000), pages 147 - 159, XP055188650
OPPOSITION- Nicolas W Warne, "Formulation development of phase 1-2 biopharmaceuticals an efficient and timely approach", Nicolas W Warne, Feroz Jameel et al, Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, (20100000), pages 147 - 159, XP055188650
OPPOSITION- WARNE N, "Development of high concentration protein biopharmaceuticais: The use of platform approaches in formulation development", European Journal of Pharmaceutics and Biopharmaceutics, (20110000), vol. 78, pages 208 - 212, XP028203394
OPPOSITION- MAARTEN A. MENSIK et al., "How sugars protect proteins in the solid state and during drying: Mechanisms of stabilization in relation to stress conditions", European Journal of Pharmaceutics and Biopharmaceutics, (20170000), vol. 114, pages 288 - 289, XP055579994
OPPOSITION- MAARTEN A. MENSIK et al., "How sugars protect proteins in the solid state and during drying: Mechanisms of stabilization in relation to stress conditions", European Journal of Pharmaceutics and Biopharmaceutics, (20170000), vol. 114, pages 289 - 295, XP055579994
OPPOSITION- "A Practical Guide on How Osmolytes Modulate Macromolecular Properties", DANIEL HARRIES et al., Methods in Cell Biology, (20080000), vol. 84, page 679 ; 680 ; 681, XP055580008
OPPOSITION- "A Practical Guide on How Osmolytes Modulate Macromolecular Properties", DANIEL HARRIES et al., Methods in Cell Biology, (20080000), vol. 84, page 679,680,681, XP055580008

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents